Tailor Made Compounding (TMC Acquisitions, LLC), Nicholasville, KY

Is Tailor Made Compounding (TMC Acquisitions, LLC) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Tailor Made Compounding (TMC Acquisitions, LLC) hold a Kentucky pharmacy license?

State board of pharmacy records for Kentucky are not checked: the board releases its license rosters only on request, and its board actions page shows nothing without running scripts. The Texas State Board of Pharmacy also lists nonresident license 33758 for TAILOR MADE COMPOUNDING, NICHOLASVILLE, KY, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054020056 for TAILOR MADE COMPOUNDING LLC, NICHOLASVILLE, KY, status CHANGE OF OWNERSHIP, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0003238 for TMC ACQUISITION, LLC (dba TAILOR MADE COMPOUNDING), NICHOLASVILLE, KY, status ACTIVE (CURRENT) and license PCN.0003894 for TMC AQUISITION LLC (dba TAILOR MADE COMPOUNDING), NICHOLASVILLE, KY, status CLOSED (WITHDRAWN), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0002095 for Tailor Made Compounding, NICHOLASVILLE, KY, status Closed, as of Nov 10, 2026.

Has Tailor Made Compounding (TMC Acquisitions, LLC) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Apr 1, 2020) for Tailor Made Compounding (TMC Acquisitions, LLC). State board of pharmacy records for Kentucky are not checked: the board releases its license rosters only on request, and its board actions page shows nothing without running scripts. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses also lists 2 actions: “Through a disciplinary action of the Board, the license is voluntarily surrendered” dated Mar 9, 2022, case AC 7091 on nonresident license NRP 1885 and “Through a disciplinary action of the Board, the license is voluntarily surrendered” dated Mar 9, 2022, case AC 7091 on nonresident license NSC 101012. The Illinois Department of Financial and Professional Regulation’s license dataset also lists “Reprimand” dated Dec 5, 2018, case 2017012116 on nonresident license 054020056.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
TMC Acquisitions, LLC; Tailor Made Compounding
Location
Nicholasville, KY
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
1
Latest action on that page
Mar 14, 2022
FDA Data Dashboard inspections
1 inspection: 1 OAI; 2 published Form 483s
Form 483 text on this page
2 Form 483s, 25 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as TMC Acquisitions, LLC dba Tailor Made Compounding, LLC, a 503A facility, with 2 dated actions.

Document
Mar 14, 2022Form 483483 Issued 03/14/2022FDA copy (archived)
Apr 1, 2020Warning letterWarning Letter (04/01/2020)FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists TMC Acquisitions LLC, Nicholasville, KY (FEI number 3012315020), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Oct 24, 2018Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30123150201069619

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 25 numbered observations in all, across 2 inspections ending Oct 24, 2018 to Mar 14, 2022. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Feb 14, 2022 to Mar 14, 2022: 13 observations

Firm on the cover
, 200 Moore Drive, Nicholasville, KY 40356-8512
FEI number
3012315020
Establishment type on the cover
Producer of Sterile and Non-Sterile Drugs
FDA district office on the cover
550 Main Street Suite 4-930 Cincinnati, OH 45202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Personnel conducted aseptic manipulations in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.

Specifically,

In the <Redacted B4> airflow ISO 5 hood your technicians were observed interrupting ISO S air in the following instances:

a. On 02/16/2022, in the <Redacted B4> ISO 5 cleanroom (<Redacted B4> room), while your technician was producing Methylcobalamin 1 mg/mL in 10 mL vials, batch 0216221 <Redacted B4> your technician was observed reaching over the opened bag of <Redacted B4> vials to grab a <Redacted B4>. This occurred two more times during production of the batch. Additionally, your technician bad their head with exposed skin inside the "ISO 5 hood" environment the entire time compounding activities were being performed. This batch of <Redacted B4> vials was quarantined by your pharmacy on 02/17/2022.

b. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Personnel manually contacted the inner surface of the container or closure.

ng production of the following sterile injectable drug products, your technicians were observed <Redacted B4> and touching the inner surface of the stoppers (a product contact surface) with their gloved hands throughout the entire <Redacted B4> process of vials containing sterile injectable drug product:

a. On 02/14/2022, in the <Redacted B4> ISO 7 cleanroom <Redacted B4> room) during sterile production of Calcium Chloride 100mg/mL in 5mL and 30mL vials, batch 0214222 , the technician <Redacted B4> vials and <Redacted B4> vials and was observed <Redacted B4> to obtain more stoppers and repeating the same activity; each time having direct gloved hand contact with the inner product contact surface of the stoppers. This batch vials pulled for testing) was released on 02/] 8/2022 and H vials were distributed to two patients in <Redacted B4> and <Redacted B4> as of 02/28/2022.

b. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Non-microbial contamination was observed in your production area.

Specifically,

a.

On 02/14/2022, the technician stated the <Redacted B4> ISO 7 cleanroom <Redacted B4> room) was clean and ready for compounding use. While the technician was producing Calcium Chloride 100mg/mL in 5mL and 30mLvials, batch 0214222 the following were observed in the ISO 7 cleanroom:

• Apparent yellow staining was observed on the HEPA filter guard inside the ISO 5 hood

• Apparent rust was observed where a metal strip outlining the door is peeling up.

• The corners of the walls were observed to be chipping and cracking.

_,c:--,-,-:-:----. • A box cutter with apparent rust on the blade, used to open a bag of <Redacted B4> stoppers and a bag of <Redacted B4> was placed inside the ISO 5 hood immediately after use during the aseptic filling process.

bag of b 4 was placed inside the ISO 5 hood immediately after use during the aseptic filling process. • Debris was found on the floor under the ISO 5 hood benchtop at the start of the <Redacted B4> filling process and consisted of an amber glass vial, a stopper, a <Redacted B4> and a E) stopper cap. ...

Read the full 483 (PDF on fda.gov)

Observation 4

You had inadequate HEPA filter coverage over the area to which sterile product was exposed.

Specifically,

a. Your <Redacted B4> airflow "ISO 5 hood", located in your <Redacted B4> ISO 5 cleanroom <Redacted B4> room), has a large square light panel in the ceiling measuring approximately 2' x 2' that breaks up the HEPA filter coverage of the benchtop inside the "ISO 5 hood." The light panel is located approximately above the middle section of the bench top where production of sterile injectable drug product is occurring. For example:

• On 02/16/2022 your technician placed the syringe on the benchtop under the large light panel, withno HEPA coverage above it, throughout the aseptic filling process for Methylcobalamin lmg/rnL,in 10mL vials, batch 0216221 <Redacted B4>. This batch was quarantined by your pharmacy on 02/l 7/2022.

b. Your ISO 5 hood, located in your <Redacted B4> ISO 7 cleanroom ( <Redacted B4>room), has two rectangular light panels in the ceiling, each measuring approximately 2' x l ', one that breaks up the HEPA filter coverage of the benchtop inside the ISO 5 hood. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.

Specifically,

a.

On 02/14/2022, the technician entered the <Redacted B4> ISO 7 cleanroom <Redacted B4> room), which contains the ISO 5 hood, from the ISO 7 anteroom with ungloved hands ( exposed skin). The while inside the ISO 7 cleanroom. The technician then proceeded to produce Calcium Chloride 100mg/mL in 5mL and 30mL vials, batch 02142220 and <Redacted B4> vials was released on 02/18/2022 and <Redacted B4> vials were distributed. The technician donned sterile gloves sterile injectable drug product This batch of <Redacted B4> vials distributed to two patients in <Redacted B4> Hand <Redacted B4> as of 02/28/2022.

b. On 02/16/2022, the technician's mask was not covering their nose in the <Redacted B4> ISO 8 prep room while producing Methylcobalamin lrng/mL in a <Redacted B4> glass beaker, batch <Redacted B4> (finished product batch 0216221 , a sterile injectable drug product. This bulk batch, used to make finished product batch 0216221 was quarantined by your pharmacy on 02/17/2022.

c. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Materials or supplies were not disinfected prior to entering the aseptic processing areas.

Specifically,

a.

For the following batches of sterile injectable drug products, your technicians were observed continuing to use the <Redacted B4> (used to simultaneously <Redacted B4> the compounded solution and fill the vials) after the tip of the <Redacted B4> touched their gloved hands and the benchtop inside the ISO 5 hood: It is routine practice for your technician's to <Redacted B4> , unscrew the <Redacted B4> from the tip of the syringe, place it on the benchtop and re-screw it to the syringe once it is refilled numerous times throughout the aseptic filling process.

• Calcium Chloride 100mg/rnL in 5mL and 30mL vials, batch 02142220 <Redacted B4> (Observed on 02/14/2022), the batch of vials and <Redacted B4> vials was released on 02/18/2022 and 30mL x 24 vials were distributed to two patients in <Redacted B4> and <Redacted B4> as of 02/28/2022.

• Metbylcobalamin 1mg/mL in 10mL vials, batch 0216221 <Redacted B4> (Observed on 02/16/2022), the batch of <Redacted B4> vials were quarantined by your pharmacy on 02/17/2022. ...

Read the full 483 (PDF on fda.gov)

Observation 7

Your facility design allowed the influx of poor quality air into a higher classified area.

Specifically,

a. In your <Redacted B4> ISO 7 cleanroom room), the ISO 5 hood is constructed with <Redacted B4> panels hanging from the ceiling to separate the ISO 5 hood from the ISO 7 cleanroom environment. Currently, there are gaps between the <Redacted B4> panels spread out across the length of the ISO 5 hood benchtop measuring approximately 0.5 inch, 1.0 inch and 1.5 inches. Additionally, there is a large gap between the bottom of the <Redacted B4> panels and the top of the ISO 5 hood benchtop, measuring approximately 2 feet. You have not evaluated the gaps to ensure lesser quality ISO 7 air is not entering the higher quality air in the ISO 5 hood environment. Your pharmacy has been routinely producing sterile injectable drug products inside this ISO 5 hood since March 3rd, 2021.

b. In your <Redacted B4> ISO 7 cleanroom <Redacted B4> room), the ISO 5 hood is constructed with <Redacted B4> panels hanging from the ceiling to separate the ISO 5 hood from the ISO 7 cleanroom environment. ...

Read the full 483 (PDF on fda.gov)

Observation 8

You produced hazardous drugs without providing adequate cleaning of utensils to prevent cross-contamination.

Specifically,

a.

On 02/16/2022 in the <Redacted B4> ISO 8 prep room, your technician was observed spraying sterile onto a <Redacted B4> wipe to wipe apparent residue off the opening of the glass beaker and proceeded to use it to compound the bulk solution for drug product Methylcobalamin 1 mg/mL, batch <Redacted B4> (finished product batch ) <Redacted B4>. The beaker had already been cleaned and <Redacted B4> and was identified as ready-to-use by the technician at the time the apparent residue was detected. The technician identified the apparent residue as possible residual Testosterone. Your pharmacy uses this <Redacted B4> beaker size to also compound the following sterile injectable drug products:

• Testosterone Cypionate/Enanthate/Propionate 80/80/40mg

• Vitamin B-Complex

• NAD+ 200mg/mL

• Semaglutide/Cyanocobalamin 2mg/0.4mg/mL

• Semaglutide/Cyanocobalamin 5mg/0.2mg/mL

• GAC 25mg/l 00mg/250mg/mL

• GOAL Injectable

• Methylcobalamin 1 0mg/mL

• Methylcobalamin lmg/mL

• Methylene Blue l0mg/mL

• BCAAs (Leucine/Iso-LeucineNaline) JOmg/J0mg/Smg/mL

• Dexpanthcnol 250mg/mL ...

Read the full 483 (PDF on fda.gov)

Observation 9

Your facility was designed and/or operated in a way that permits poor flow of personnel and materials.

Specifically,

a. On 02/14/2022, while your technician was producing CaJcium Chloride lO0mg/rnL in 5mL and 30mL vials, batch <Redacted B4> , your technician left the <Redacted B4> ISO 7 cleanroom <Redacted B4> room) with exposed sterile injectable product vials on the ISO 5 hood benchtop, walked through the ISO 7 anteroom and into the <Redacted B4> ISO 5 cleanroom <Redacted B4> room) to grab a bag of stoppers. Your technician was observed bringing the bag of stoppers into the ISO 7 cleanroom without wiping the bag down and using the stoppers to complete production of the batch.

b. On 02/16/2022, while your technician was producing Methylcobalamin 10mL vials, batch 0216221 <Redacted B4> your technician held the door to the <Redacted B4> ISO 5 cleanroom <Redacted B4> room) open and grabbed a blue plastic bin off a metal shelfing rack in the ISO 7 anteroom. Your technician was observed placing this blue plastic bin on the "ISO 5 hood" benchtop without sanitizing it first. ...

Read the full 483 (PDF on fda.gov)

Observation 10

Environmental monitoting was not perfonned in your aseptic processing areas.

Specifically,

Accordjng to your firm's QA/QC Manager, Environmental Morutoring (i.e., surface samples) is conducted by your vendor every <Redacted B4> but <Redacted B4>. Therefore results are not representative of the aseptic processing environment making the results unreliable. Additionally, your pharmacy is currently incubating <Redacted B4> plates for an period that could the plates out making results inconclusive <Redacted B4> plates are being incubated for approximately <Redacted B4> at <Redacted B4> and then for approximately <Redacted B4> at <Redacted B4>, for <Redacted B4> total incubation time.

Observation 11

ISO 5 classified areas were not adequately certified under dynamic conditions to demonstrate unidirectional airflow.

Specifically,

Smoke studies in the <Redacted B4> ISO 7 cleanroom and <Redacted B4> ISO 5 cleanroom showed air turbulence within the <Redacted B4> airflow ISO 5 hood environment with smoke raising up in the ISO 5 hood and lingering as well as spreading out over the ISO 5 hood benchtop. Additionally, the <Redacted B4> ISO 5 cleanroom certification performed in January 2022 did not meet air changes per <Redacted B4> recommendations of <Redacted B4> to maintain the ISO 5 environment; result for the cleanroom was 57 ACH.

Your pharmacy's drug products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.

Observation 12

Media fills are not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.

Specifically,

Your pharmacy's media fill dated 02/09/2022, conducted in the <Redacted B4> ISO 7 cleanroom , and media fill dated 02/28/2022, conducted in the <Redacted B4> ISO 7 cleanroo fails to closely simulate current aseptic operations. The media fills were conducted with only vials. Per your firm's batch size range of vials, the average batch size for sterile injectable drug products is approximately vials. Prior to 01/05/2022, your pharmacy was only using vials during media fills. After this date, your pharmacy increased media fills <Redacted B4> vials. Then on 02/15/2022 and per SOP 7.008 "Media Fill for High Risk Compounding", version 3, your pharmacy increased media fills <Redacted B4> vials, on!y of the approximate average batch size of vials and is still using this batch size for media fills presently.

Observation 13

You used a non-pharmaceutical grade component in the formuation a drug product.

Specifically,

a. On 02/22/23, your pharmacy produced sterile injectable drug product Methylcobalamin 10mg/mL, batch number 02222207 <Redacted B4> , using <Redacted B4> batch number <Redacted B4> for parenteral use. The COA for <Redacted B4> specifically states, "Product not intended for Parenteral use." This Metbylcobalamin batch of <Redacted B4>. vials pulled for testing) was released and vials were distributed to patients in states as of 03/09/2022. In total, your pharmacy used this batch <Redacted B4> ( <Redacted B4> to produce batches of drug products sterile injectable drug products and nasal spray drug products), out of which batches have been released and distributed to patients.

b. On 02/23/2022, your pharmacy produced two batches of sterile injectable drug product Semaglutide/Cyanobalarnin 5mg/0.2mg/mL in 2mL vials, batches 02232210 <Redacted B4> and 02232202 <Redacted B4> , using <Redacted B4>, batch number <Redacted B4> , for parenteral use on patients. ...

Read the full 483 (PDF on fda.gov)

Inspection Aug 20, 2018 to Oct 24, 2018: 12 observations

Firm on the cover
Tailor Made Compounding, LLC, 200 Moore Drive, Nicholasville, KY 40356-8512
FEI number
3012315020
Establishment type on the cover
Producer of Sterile Drugs
FDA district office on the cover
6751 Steger Drive Cincinnati, OH 45237-3097
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Investigations of an unexplained discrepancy and a failure of a batch or any of its components to meet any of its specifications did not extend to other batches of the same drug product and other diug products that may have been associated with the specific failure or discrepancy.

Specifically, your firm has documented 5 sterility failures since January 2016 to present.

Date

Product

Lot Number

Sterility Failure Date

Compounded

Thymosin Alpha

IGF-1

IGF-1 LR3

BPC-157

HCG-4000

Your firm does not evaluate other products that were produced in the same time-period in which the sterility failure occuned. Per firm management, your firm performs a cleaning after a sterility failure, however, there is no written documentation that this additional cleaning of your ISO 5 and ISO 7 areas is performed.

is perfo1med.

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

a.) Your firm does not have any hold time studies for how long stoppers, vials and seals (caps) can be stored after being <Redacted B4> prior to being used in sterile operations. On 8/21/18, we observed your pharmacy technician using the <Redacted B4> In sterile operations while producing Thymosin Beta Injectable (lot# 0821201806), by <Redacted B4> with their gloved hands.

b.) Media fills do not simulate your sterile operations process under normal operating conditions. Your media fills are not performed under worst case aseptic processing conditions, for example, your firm produces batches that consists of <Redacted B4> of yials during normal sterile operations under the ISO 5 4 hood, whereas your media fill consists of only vials being filled and does not incorporate any interventions that may occur during sterile operations.

c.) Your firm does not include the <Redacted B4> into the media fill program. No media fills are performed on the <Redacted B4> process. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Protective apparel is not worn as necessai·y to protect drug products from contamination.

'(b

Observation 4

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.

a.) Specifically, smoke studies are conducted every <Redacted B4> by a third-party. Your firm's smoke studies were performed on <Redacted B4> Prior to November 2017 your film did not perfo1m smoke studies. Your firm does not perform smoke studies under dynamic conditions. We reviewed your firm's smoke studies and they were brief and had no description of what action was being performed. Furthermore, while viewing these smoke studies, it was difficult to see smoke on various occasions.

b.) Also, your firm does not include the <Redacted B4> process in your smoke studies. Your firm <Redacted B4> two products, Tesamorelin and HCG using a <Redacted B4> related inside the ISO 5 hood. The process includes <Redacted B4> vials from the <Redacted B4> and vial <Redacted B4> vial <Redacted B4> the <Redacted B4>

Your smoke studies are performed under static conditions and do not incorporate the <Redacted B4> process nor any dynamic conditions to evaluate the efficiency of your HEPA airflow.

Observation 5

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically, your firm's bactericidal agent <Redacted B4> used for cleaning is not sterile. Your firm uses <Redacted B4> for cleaning the ISO 5 hood, ISO 7 rooms and ISO 8 rooms.

Observation 6

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

a.) Specifically, your firm only conducts personnel monitoring every <Redacted B4> on each individual that performs sterile operations. No other personnel monitoring is performed besides this <Redacted B4> monitoring. Your firm does not document the time when personnel monitoring is performed (i.e. before sterile operations, during sterile operations or after sterile operations). Your firm's personnel monitoring consists of finger tips only. No other areas such as forehead, mask, or chest are monitored for the operators.

b.) Your firm does not have alarms connected to your magnehelic gauges to monitor pressure differentials during production. Furthermore, your firm only records the room pressures in the aseptic processing areas <Redacted B4> and does not monitor the magnehelic gauges during production.

Observation 7

Specifically, on 9/11/18, we observed <Redacted B4> vials of Tesamorelin 1 mg subcutaneous injection (batch 07161804; BUD Date 07/12) stored in the refrigerator in your pharmacy. The Beyond 4 Use Date (BUD) on each of the <Redacted B4> fesamorelin vial labels of this lot contained an inconect one-year BUD date, while the conect BUD date for Tesamorelin is 180 days.

Your firm began using a new computer program called <Redacted B4> on or about 7/6/18 for printing labels to be affixed to finished product vials. When this issue was brought to your management's attention, your firm conducted an investigation which identified that any Tesamorelin product produced and shipped between 7 /6/18 to 9/11/18 contains the inconect one year BUD date, due to an installation error of the new computer program.

Observation 8

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

Specifically, your firm performs potency testing at various random intervals on products produced. However, there is no set schedule or frequency for when potency testing will be performed. Your firm's specification for potency is <Redacted B4> Your firm released 3 products to patients with Out-of-Specification (OOS) potency results.

Product

Lot Number

Sterile /Non -Sterile

BUD Date

Date Produced

Test Date

Test Result

Released to patients

Yes <Redacted B4> patients 92.5% 88.0%

Glutathione 200mg Injection

90 Days

Sterile

Glutathione 200mg Injection

Days 90 Days 88.0% patient DHEA 75 mg capsules

180 Days

Non -Sterile

86.1%

Yes <Redacted B4> patients

Alprostadil/Paparerine/ Phentolamine Injection 60mcg, 30 mg, 3 mg

60 Days Sterile

11/27/17 12/26/1 7 95.2% 83.2%

Yes <Redacted B4> patient

Furthermore, on potency results that are OOS your firm does not have a procedure in place on how to handle these failed results. ...

Read the full 483 (PDF on fda.gov)

Observation 9

Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

a.) Specifically, your firm does not perform any identity testing on incoming raw materials.

b.) Your firm receives raw materials and peptides from suppliers both domestically and internationally. However, your firm has never audited any of these suppliers.

Observation 10

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, there is no written stability program designed to assess the stability characteristics of drug products. For example, Glutathione 200mg Injection (lot 12191702) was not within its BUD date with a 88.0% potency result on 2/12/18 and Alprostadil/Paparerine/Phentolamine Injection 60mcg, 30 mg, 3 mg (lot 11141713) was not within its BUD date with a 83.2% potency result on 12/26/17.

88.0% potency result on 2/12/18 and Alprostadil/Paparerine/Phentolamine Injection 60mcg, 30 mg, 3 mg (lot 11141713) was not within its BUD date with a 83.2% potency result on 12/26/17.

Sterile/Non-~ Sterile Date Produced

Released to patients

Product

Lot Number

BUD DATE

Test Date

Test Result

Glutathione 200mg Injection

90 Days

Sterile 12/19/17

92.5% 88.0%

Yes <Redacted B4> patient

Alprostadil/Paparerine/ Phentolamine Injection 60mcg, 30 mg, 3 mg

60 Days

Sterile 11/14/17

95.2%

Yes <Redacted B4> patient

83.2%

Observation 11

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

Specifically, your firm does not have any hold time studies for how long glassware used for sterile operations can be stored before use after being depyrogenated in the <Redacted B4> Furthermore, your firm has not performed any studies to assure a 3-log reduction is achieved for endotoxins.

Observation 12

Routine calibration of equipment is not performed according to a written program designed to assure proper performance.

a.) Specifically, your firm uses <Redacted B4> or sterile operations of all high-risk sterile products (non-sterile to sterile products). The <Redacted B4> Temp pressure gauge (Serial Number: <Redacted B4> used for performing the <Redacted B4> (post sterile operations) has never been calibrated. This pressure gauge has been used since your firm began operations in January 2016. Also, your firm does not receive a Certificate of Analysis for <Redacted B4> used for sterile operations.

b.) Equipment used in sterile operations are not on a calibration program to be calibrated at any frequency. The following pieces of equipment have not been calibrated since your firm began operations in January 2016 <Redacted B4> incubators, and <Redacted B4> . Your <Redacted B4> scale (model #{t>) (4t serial number <Redacted B4> used for weighing materials for sterile operations is past due for calibration. On 8/21/18, we observed this scale had a due date sticker of 7 /31/18. ...

Read the full 483 (PDF on fda.gov)

State board of pharmacy records

State board of pharmacy records for Kentucky are not checked: the board releases its license rosters only on request, and its board actions page shows nothing without running scripts.

Nonresident licenses and board actions in other states

These boards list a nonresident license or a board action whose record names this pharmacy’s own name, city and state.

Texas State Board of Pharmacy, file dated Nov 15, 2026 (Texas).

LicenseType as the board gives itName on the board recordLocationStatusPrior disciplinary orders (file flag)
33758Non Resident Sterile CompoundingTAILOR MADE COMPOUNDINGNICHOLASVILLE, KYActiveNo

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054020056LICENSED PHARMACYTAILOR MADE COMPOUNDING LLCNICHOLASVILLE, KYCHANGE OF OWNERSHIP

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0003238NONRESIDENT PHARMACYTMC ACQUISITION, LLC (dba TAILOR MADE COMPOUNDING)NICHOLASVILLE, KYACTIVE (CURRENT)
PCN.0003894NONRESIDENT PHARMACYTMC AQUISITION LLC (dba TAILOR MADE COMPOUNDING)NICHOLASVILLE, KYCLOSED (WITHDRAWN)

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0002095Non Resident PharmacyTailor Made CompoundingNICHOLASVILLE, KYClosed

GLP-1 warning letters

FDA’s posted warning letters that name a GLP-1 drug include 0 letters to TMC Acquisitions LLC dba Tailor Made Compounding. See the TMC Acquisitions LLC dba Tailor Made Compounding record page for those letters and any recalls.

No FDA warning letters in this index.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.